Narcolepsy and syndromes of primary excessive daytime somnolence

Seminars in Neurology

Volumn 24, Issue 3, 2004, Pages 271-282

  Black, Jed E ^a,b   Brooks, Stephen N ^a   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Cataplexy; Excessive daytime sleepiness; Hypersomnia; Narcolepsy; Sleep; Somnolence

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DIAZEPAM BINDING INHIBITOR; ESTROGEN; FLUMAZENIL; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DR11 ANTIGEN; LITHIUM; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OREXIN; OXYBATE SODIUM; PEMOLINE; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE;

ANOREXIA; ANXIETY; CATAPLEXY; CLINICAL FEATURE; DEGENERATIVE DISEASE; DRUG HALF LIFE; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; GENE MUTATION; GENE TARGETING; HEADACHE; HEART PALPITATION; HUMAN; HYPERSOMNIA; HYPERTENSION; HYPNAGOGIC HALLUCINATION; INSOMNIA; IRRITABILITY; MENSTRUAL CYCLE; NARCOLEPSY; NAUSEA; NEUROLOGIC DISEASE; NIGHT SLEEP; NONHUMAN; PARASOMNIA; PERFUSION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PTOSIS; QUALITY OF LIFE; REM SLEEP; REVIEW; SEDATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DEPRIVATION; SLEEP PARAMETERS; SLURRED SPEECH; SOMNOLENCE; STUPOR; SUSTAINED RELEASE PREPARATION; TACHYPHYLAXIS; TREMOR; TRYPANOSOMIASIS;

ANIMALS; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; NARCOLEPSY; SYNDROME;

EID: 5044232919     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835069     Document Type: Review

References (92)

1. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994;35:709-716
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(suppl 1):S16-S22
3. International Classification of Sleep Disorders (ICSD). Diagnostic and Coding Diagnostic Classification Steering Committee (Thorpy MJ, chairman). American Sleep Disorders Association. Narcolepsy 1990;347:38-43
4. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-765
5. US Xyrem in Narcolepsy Multi-center Study Group. A randomized, double blind, placebo controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-49
6. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545
7. Honda Y. Clinical features of narcolepsy: Japanese experiences. In: Honda Y, Juji T, eds. HLA in Narcolepsy. Berlin: Springer-Verlag; 1988:24-57
8. Gelb M, Guilleminault C, Kraemer H, et al. Stability of cataplexy over several months: information for the design of therapeutic trials. Sleep 1994;17:265-273
9. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiological insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105
10. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
11. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562
12. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50:S16-S22
13. Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest 1993;104:781-787
14. Roth B. Narcolepsy and hypersomnia. Schweiz Arch Neurol Neurochir Psychiatr 1976;119:31-41
15. Aldrich MS. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996;46:393-401
16. Montplaisir J, Poirier G. HLA in disorders of excessive sleepiness without cataplexy in Canada. In: Honda Y, Juji T, eds. HLA in Narcolepsy. Berlin: Springer-Verlag; 1988:186
17. Montplaisir J, De Champlain J, Young SN, et al. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF. Neurology 1982;32:1299-1302
18. Faull KF, Guilleminault C, Berger PA, Barchas JD. Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia. Ann Neurol 1983;13:258-263
19. Faull KF, Thiemann S, King RJ, Guilleminault C. Monoamine interactions in narcolepsy and hypersomnia: a preliminary report. Sleep 1986;9:246-249
20. Bruck D, Parkes JD. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data. J Neurol Neurosurg Psychiatry 1996;60:576-578
21. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain 1997;120:1423-1435
22. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001;5:349-358
23. Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with "sleep drunkenness". Arch Gen Psychiatry 1972;26:456-462
24. Sforza E, Gaudreau H, Petit D, Montplaisir J. Homeostatic sleep regulation in patients with idiopathic hypersomnia. Clin Neurophysiol 2000;111:277-282
25. Sangal RB, Sangal JM. P300 latency: abnormal in sleep apnea with somnolence and idiopathic hypersomnia, but normal in narcolepsy. Clin Electroencephalogr 1995;26:146-153
26. Critchley M. The syndrome of hypersomnia and periodical megaphagia in the adult male (Kleine-Levin): what is its natural course? Rev Neurol 1967;116:647-650
27. Rosenow F, Kotagal P, Cohen BH, Green C, Wyllie E. Multiple sleep latency test and polysomnography in diagnosing Kleine-Levin syndrome and periodic hypersomnia. J Clin Neurophysiol 2000;17:519-522
28. Arias M, Crespo Iglesias JM, Perez J, Requena-Caballero I, Sesar-Ignacio A, Peleteiro-Fernandez M. Klein-Levin syndrome: contribution of brain SPECT in diagnosis. Rev Neurol 2003;35:531-533
29. Billiard M, Guilleminault C, Dement WC. A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or a new clinical entity? Neurology 1975;25:436-443
30. Sachs C, Persson H, Hagenfeldt K. Menstruation-associated periodic hypersomnia: a case study with successful treatment. Neurology 1982;32:1376-1379
31. Bamford CR. Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide. Sleep 1993;16:484-486
32. Rothstein JD, Guidotti A, Tinuper P, et al. Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor. Lancet 1992;340:1002-1004
33. Lugaresi E, Montagna P, Tinuper P, et al. Endozepine stupor. Recurring stupor linked to endozepine-4 accumulation. Brain 1998;121:127-133
34. Soriani S, Carrozzi M, De Carlo L, et al. Endozepine stupor in children. Cephalalgia 1997;17:658-661
35. Francisco GE, Ivanhoe CB. Successful treatment of post-traumatic narcolepsy with methylphenidate: a case report. Am J Phys Med Rehabil 1996;75:63-65
36. Manni R, Tantara A. Evaluation of sleepiness in epilepsy. Clin Neurophysiol 2000;111(suppl 2):S111-S114
37. Toth LA, Opp MR. Sleep and infection. In: Lee-Chiong TL, Sateia MJ, Carskadon MA, eds. Sleep Medicine. Philadelphia: Hanley & Belfus; 2002:77-83
38. Guilleminault C, Mondini S. Mononucleosis and chronic daytime sleepiness: a long term follow-up study. Arch Intern Med 1986;146:1333-1335
39. Askenasy JJM. Sleep in Parkinson's disease. Acta Neurol Scand 1993;87:167-170
40. Chokroverty S. Sleep and degenerative neurologic disorders. Neurol Clin 1996;14:807-826
41. Trenkwalder C. Sleep dysfunction in Parkinson's disease. Clin Neurosci 1998;5:107-114
42. George CFP. Neuromuscular disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia: WB Saunders Co; 2000:1087-1092
43. Gibbs JW, Ciafaloni E, Radtke RA. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep 2002;25:672-675
44. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA Standards of Practice. Sleep 1994;17:352-371
45. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
46. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
47. Tunnicliff G, Cash CD. Gamma-hydroxybutyrate: Molecular, Functional and Clinical Aspects. New York: Taylor and Francis; 2002
48. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78
49. Dement W, Rechtschaffen A, Gulevich G. The nature of the narcoleptic sleep attack. Neurology 1966;16:18-33
50. Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W. Excessive daytime sleepiness and pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 1986;9:205-215
51. Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch Neurol 1974;31:255-261
52. Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res 2000;38:437-446
53. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562
54. Fukuda K, Miyasita A, Inugami M, Ishihara K. High prevalence of isolated sleep paralysis: Kanashibari phenomenon in Japan. Sleep 1987;10:279-286
55. Bishop C, Rosenthal L, Helmus T, Roehrs T, Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996;19:727-730
56. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena? Br J Psychiatry 1996;169:459-467
57. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997;20:620-629
58. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984;24:316-319
59. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA Class II studies in 509 narcoleptic patients. Sleep Res 1997;26:433
60. Mignot E, Guilleminault C, Grumet FC, Dement WC. Is narcolepsy an autoimmune disease? In: Smirne S, Francesci M, Ferini-Strambi L, Zucconi M, eds. Proceedings of the Third Milano International Symposium, September 18-19. "Sleep, Hormones, and the Immune System." Milan: Masson; 1992:29-38
61. Frederickson S, Carlander B, Billiard M, Link H. CSF immune variable in patients with narcolepsy. Acta Neurol Scand 1990;81:253-254
62. Matsuki K, Juji T, Honda Y. Immunological features of narcolepsy in Japan. In: Honda Y, Juji T, eds. HLA in Narcolepsy. Berlin: Springer-Verlag; 1988:150-157
63. Billiard M, Laaberki MF, Reygrobellet C, Seignalet J, Brissaud L, Besset A. Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 1989;18:201
64. Montplaisir J, Poirier G, Lapierre O, Montplaisir S. Streptococcal antibodies in narcolepsy and idiopathic hypersomnia. Sleep Res 1989;18:271
65. Mignot E, Wang C, Rattazzi C, et al. Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin heavy-chain switch-like segment. Proc Natl Acad Sci USA 1991;88:3475-3478
66. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-451
67. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-376
68. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997
69. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000;355:39-40
70. Nishino S, Ripley B, Overeem S, et al. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001;50:381-388
71. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002;11:91-93
72. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002;25:733-736
73. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-474
74. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8:525-534
75. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin levels in various neurological conditions: low levels in narcolepsy and Guillain-Barre syndrome. Sleep 2001b;24:A322
76. Alaila SL. Life effects of narcolepsy: measures of negative impact, social support and psychological well-being. In: Goswanmi M, Pollak CP, Cohen FL, Thorpy MJ, Kavey NB, eds. Loss, Grief and Care: Psychosocial Aspects of Narcolepsy. New York: Haworth Press; 1992:1-22
77. De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998;95:322-327
78. Sakurai T, Amemiya A, Ishil M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein coupled receptors that regulate feeding behavior. Cell 1998;92:573-585
79. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015
80. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001;24:429-458
81. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002;25:283-313
82. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78
83. Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci 2001;21:9273-9279
84. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 2001;98:9965-9970
85. Yamanaka A, Tsujino N, Funahashi H, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 2002;290:1237-1245
86. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001;313:125-128
87. Tedford CE, Edgar DM, Seidel WF, et al. Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy. Soc Neurosci Abstr 1999;25:1134
88. Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 2001;12:993-997
89. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001;14:1075-1081
90. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 2003;23:3555-3560
91. Aston-Jones G, Chen S, Zhu Y, Oshinsky ML. A neural circuit for circadian regulation of arousal. Nat Neurosci 2001;4:732-738
92. Wu MF, John J, Maidment N, Lam HA, Siegel JM. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol 2002;283:R1079-R1086